Oncology 12/2018 FASN inhibition as a potential treatment for therapy of endocrine resistant breast cancer San Antonio Breast Cancer Symposium natalia Love10
Oncology 11/2018 Updated results from a prospective, randomized phase 2 study in patients with first relapse of high-grade astrocytoma using TVB-2640 in combination with Avastin versus Avastin alone Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology natalia Love8
Oncology 02/2017 Fatty Acid Synthase – Modern Tumor Cell Biology Insights into a Classical Oncology Target Pharmacology and Therapeutics natalia Love8
Oncology 12/2016 FASN inhibition and taxane treatment combine to enhance anti-tumor efficacy in diverse xenograft tumor models through disruption of tubulin palmitoylation and microtubule organization and FASN inhibition-mediated effects on oncogenic signaling and gene expression EBioMedicine natalia Love6
Oncology 09/2016 Mechanism and rationale for inhibition of FASN as a novel therapy for KRAS-mutant non-small cell lung cancer patients Precison: Lung Cancer R&D Summit natalia Love6
Oncology 08/2016 DeNovo Palmitate Synthesis Supports Oncogenic Signaling Through Diverse Mechanisms: Implications for FASN-Targeted Therapeutics Journal of Cell Signaling natalia Love6
Virology 12/2015 Direct Inhibition of Cellular Fatty Acid Synthase Impairs Replication of Respiratory Synctial Virus and Other Respiratory Viruses PLOS ONE natalia Love5
Oncology 06/2015 First-in-Human Investigation of the Oral First-in-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 ASCO Annual Meeting natalia Love6
Oncology 11/2014 Initial report of a first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640 EORTC-NCI-AACR International Conference natalia Love4
Oncology 11/2014 Mechanistic analysis of reversible FASN inhibition in preclinical tumor models identifies highly susceptible tumor types and enriches biomarker discovery for clinical applications EORTC-NCI-AACR International Conference natalia Love4